Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients

BMJ Open Diabetes Research and Care

Volumn 5, Issue 1, 2017, Pages

  Garg, Rajesh ^a   Schuman, Brooke ^a   Hurwitz, Shelley ^a   Metzger, Cheyenne ^a   Bhandari, Shreya ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; INSULIN; SAXAGLIPTIN;

AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC KETOACIDOSIS; DIETARY INTAKE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLYCEMIC CONTROL; HOSPITAL PATIENT; HUMAN; HYPERGLYCEMIA; HYPEROSMOLARITY; HYPOGLYCEMIA; INSULIN TREATMENT; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 85037638577     PISSN: None     EISSN: 20524897     Source Type: Journal    
DOI: 10.1136/bmjdrc-2017-000394     Document Type: Article

References (24)

1. Ishihara M, Kojima S, Sakamoto T, et al. Acute hyperglycemia is associated with adverse outcome after acute myocardial infarction in the coronary intervention era. Am Heart J 2005;150:814-20.
2. Garg R, Bhutani H, Alyea E, et al. Hyperglycemia and length of stay in patients hospitalized for bone marrow transplantation. Diabetes Care 2007;30:993-4.
3. Umpierrez GE, Isaacs SD, Bazargan N, et al. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002;87:978-82.
4. Williams LS, Rotich J, Qi R, et al. Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. Neurology 2002;59:67-71.
5. Ascione R, Rogers CA, Rajakaruna C, et al. Inadequate blood glucose control is associated with in-hospital mortality and morbidity in diabetic and nondiabetic patients undergoing cardiac surgery. Circulation 2008;118:113-23.
6. Krinsley JS. Translating evidence into practice in managing inpatient hyperglycemia. J Hosp Med 2007;2(Suppl 1):13-19.
7. Umpierrez GE, Smiley D, Jacobs S, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care 2011;34:256-61.
8. Murad MH, Coburn JA, Coto-Yglesias F, et al. Glycemic control in non-critically ill hospitalized patients: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012;97:49-58.
9. Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes care 2009;32:1119-31.
10. Umpierrez GE, Hellman R, Korytkowski MT, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2012;97:16-38.
11. American Diabetes Association. 13. Diabetes Care in the Hospital. Diabetes Care 2016;39:S99-S104.
12. D'Ancona G, Bertuzzi F, Sacchi L, et al. Iatrogenic hypoglycemia secondary to tight glucose control is an independent determinant for mortality and cardiac morbidity. Eur J Cardiothorac Surg 2011;40:360-6.
13. Garg R, Hurwitz S, Turchin A, et al. Hypoglycemia, with or without insulin therapy, is associated with increased mortality among hospitalized patients. Diabetes Care 2013;36:1107-10.
14. Turchin A, Matheny ME, Shubina M, et al. Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. Diabetes Care 2009;32:1153-7.
15. Farrokhi F, Chandra P, Smiley D, et al. Glucose variability is an independent predictor of mortality in hospitalized patients treated with total parenteral nutrition. Endocr Pract2014;20:41-5.
16. Mendez CE, Mok KT, Ata A, et al. Increased glycemic variability is independently associated with length of stay and mortality in noncritically ill hospitalized patients. Diabetes Care 2013;36:4091-7.
17. Hill NR, Oliver NS, Choudhary P, et al. Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. Diabetes Technol Ther 2011;13:921-8.
18. https://www.phc.ox.ac.uk/research/technology-outputs/easygv [article online].
19. Sampson MJ, Singh H, Dhatariya KK, et al. Psychometric validation and use of a novel diabetes in-patient treatment satisfaction questionnaire. Diabet Med 2009;26:729-35.
20. Umpierrez GE, Gianchandani R, Smiley D, et al. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study. Diabetes Care 2013;36:3430-5.
21. Pasquel FJ, Gianchandani R, Rubin DJ, et al. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol 2017;5:125-33.
22. Pasquel FJ, Gomez-Huelgas R, Anzola I, et al. Predictive value of admission hemoglobin A1c on inpatient glycemic control and response to insulin therapy in medicine and surgery patients with type 2 diabetes. Diabetes Care 2015;38:e202-203.
23. Nauck MA, Meier JJ. Sitagliptin plus basal insulin: simplifying in-hospital diabetes treatment? Lancet Diabetes Endocrinol 2017;5:83-5.
24. Garg R, Chaudhuri A, Munschauer F, et al. Hyperglycemia, insulin, and acute ischemic stroke: a mechanistic justification for a trial of insulin infusion therapy. Stroke 2006;37:267-73.